PremiumThe FlyNyxoah reports Q1 EPS (EUR 0.60) vs. (EUR 0.42) last year Nyxoah Announces Changes in Shareholding by FMR LLC Nyxoah SA Schedules Shareholders’ Meetings for June 2025 PremiumThe FlyNyxoah anticipates FDA approval for Genio system in Q2 Nyxoah price target lowered to $15 from $17 at H.C. Wainwright Nyxoah’s Strategic Positioning and Growth Potential in the Obstructive Sleep Apnea Market PremiumCompany AnnouncementsNyxoah Reports 2024 Financial Results and U.S. Launch Plans Nyxoah Sa’s Earnings Call: Efficacy and Expansion Nyxoah’s Strategic Expansion and U.S. Market Potential Drive Buy Rating